Jasmanda Wu

955 total citations
32 papers, 660 citations indexed

About

Jasmanda Wu is a scholar working on Endocrinology, Diabetes and Metabolism, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jasmanda Wu has authored 32 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Epidemiology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jasmanda Wu's work include Diabetes Treatment and Management (9 papers), Diabetes Management and Research (8 papers) and Cystic Fibrosis Research Advances (4 papers). Jasmanda Wu is often cited by papers focused on Diabetes Treatment and Management (9 papers), Diabetes Management and Research (8 papers) and Cystic Fibrosis Research Advances (4 papers). Jasmanda Wu collaborates with scholars based in United States, France and United Kingdom. Jasmanda Wu's co-authors include Fun Man Fung, Ken Hornbuckle, Anna Thornton, William H. Herman, Mary N. Haan, Debashis Ghosh, Hector M. González, Jersey Liang, Héctor M. González and Jersey Liang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Diabetes Care.

In The Last Decade

Jasmanda Wu

30 papers receiving 627 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jasmanda Wu United States 11 166 109 92 81 74 32 660
Victoria Zarotsky United States 20 354 2.1× 168 1.5× 166 1.8× 96 1.2× 92 1.2× 39 1.3k
Siegfried Schmidt United States 15 151 0.9× 97 0.9× 75 0.8× 241 3.0× 129 1.7× 43 910
Jens Bos Netherlands 18 98 0.6× 156 1.4× 47 0.5× 73 0.9× 45 0.6× 74 834
Emmanuelle Bondon‐Guitton France 17 48 0.3× 98 0.9× 63 0.7× 80 1.0× 45 0.6× 44 834
Ashish Kumar Kakkar India 16 52 0.3× 86 0.8× 178 1.9× 113 1.4× 67 0.9× 72 976
C Aguirre Spain 18 70 0.4× 140 1.3× 72 0.8× 47 0.6× 67 0.9× 55 846
Deepak Gopal Shewade India 17 132 0.8× 55 0.5× 129 1.4× 25 0.3× 58 0.8× 68 708
G. L. Pearce United Kingdom 18 81 0.5× 115 1.1× 69 0.8× 107 1.3× 57 0.8× 28 888
Sang-Goo Shin South Korea 17 141 0.8× 95 0.9× 193 2.1× 55 0.7× 32 0.4× 47 752
Daniël M. Jonker Denmark 10 109 0.7× 152 1.4× 224 2.4× 54 0.7× 43 0.6× 19 890

Countries citing papers authored by Jasmanda Wu

Since Specialization
Citations

This map shows the geographic impact of Jasmanda Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasmanda Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasmanda Wu more than expected).

Fields of papers citing papers by Jasmanda Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasmanda Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasmanda Wu. The network helps show where Jasmanda Wu may publish in the future.

Co-authorship network of co-authors of Jasmanda Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Jasmanda Wu. A scholar is included among the top collaborators of Jasmanda Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasmanda Wu. Jasmanda Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wu, Jasmanda, Lei Wu, & Aihua Hu. (2024). EE759 Cost-Effectiveness of Tezepelumab in Taiwan for Severe Asthma. Value in Health. 27(12). S204–S204.
3.
Wu, Jasmanda, et al.. (2024). Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension. Pulmonary Therapy. 10(3). 315–330. 1 indexed citations
4.
Flume, Patrick A., et al.. (2023). Pulmonary exacerbations in insured patients with bronchiectasis over 2 years. ERJ Open Research. 9(4). 21–2023. 6 indexed citations
5.
6.
Escalada, Javier, Fabrice Bonnet, Jasmanda Wu, et al.. (2020). Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. Advances in Therapy. 37(9). 3863–3877. 4 indexed citations
7.
Mauricio, Dı́dac, et al.. (2020). How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real‐world setting?. Diabetes Obesity and Metabolism. 23(3). 838–843. 5 indexed citations
8.
Bailey, Timothy S., Jasmanda Wu, Fang Liz Zhou, et al.. (2019). Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3). Diabetes Obesity and Metabolism. 21(11). 2384–2393. 24 indexed citations
9.
Tang, Hong, et al.. (2018). Long-Term Outcomes Associated with Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C in China. Value in Health. 21. S65–S65. 3 indexed citations
10.
Escalada, Javier, Fabrice Bonnet, Jasmanda Wu, et al.. (2018). PDB11 - CHART REVIEW ANALYSIS OF INSULIN GLARGINE 300 AND INSULIN GLARGINE 100 USE IN FRANCE, SPAIN, AND GERMANY. Value in Health. 21. S120–S120. 1 indexed citations
11.
Wu, Jasmanda. (2017). The changing epidemiology of hepatocellular carcinoma in Asia versus United States and Europe. SHILAP Revista de lepidopterología. 3(s1). 51–51. 10 indexed citations
12.
Wu, Jasmanda, et al.. (2015). Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. Cancer Epidemiology. 39(2). 242–249. 20 indexed citations
13.
Wu, Jasmanda, Wanju S. Dai, Andrew Koren, et al.. (2014). Assessment of Dronedarone Utilization Using US Claims Databases. Clinical Therapeutics. 36(2). 264–272.e2. 7 indexed citations
14.
Wu, Jasmanda, et al.. (2011). P2‐119: Occurrence of nonmelanoma skin cancer in the elderly with and without Alzheimer's Disease in the US. Alzheimer s & Dementia. 7(4S_Part_10). 1 indexed citations
15.
Gianfrancesco, Frank D., et al.. (2009). Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study. Annals of General Psychiatry. 8(1). 5–5. 11 indexed citations
16.
Tice, Alan D., et al.. (2007). Comparative costs of ertapenem and piperacillin–tazobactam in the treatment of diabetic foot infections. American Journal of Health-System Pharmacy. 64(10). 1080–1086. 23 indexed citations
17.
Wu, Jasmanda, Man C. Fung, Wenyaw Chan, & David R. Lairson. (2004). Cost-Effectiveness Analysis of Interventions to Enhance Mammography Compliance Using Computer Modeling (CAN*TROL). Value in Health. 7(2). 175–185. 10 indexed citations
18.
19.
Wu, Jasmanda, Mary N. Haan, Jersey Liang, et al.. (2003). Impact of Antidiabetic Medications on Physical and Cognitive Functioning of Older Mexican Americans with Diabetes Mellitus. Annals of Epidemiology. 13(5). 369–376. 61 indexed citations
20.
Wu, Jasmanda, Mary N. Haan, Jersey Liang, et al.. (2003). Impact of diabetes on cognitive function among older Latinos. Journal of Clinical Epidemiology. 56(7). 686–693. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victoria Zarotsky Breakdown of academic impact, for papers by Siegfried Schmidt Breakdown of academic impact, for papers by Jens Bos Breakdown of academic impact, for papers by Emmanuelle Bondon‐Guitton Breakdown of academic impact, for papers by Ashish Kumar Kakkar Breakdown of academic impact, for papers by C Aguirre Breakdown of academic impact, for papers by Deepak Gopal Shewade Breakdown of academic impact, for papers by G. L. Pearce Breakdown of academic impact, for papers by Sang-Goo Shin Breakdown of academic impact, for papers by Daniël M. Jonker
Rankless by CCL
2026